Eligibility

Eligible Ages

Over 18 Years

Eligible Sex

All

Accepts Healthy Volunteers

No

Criteria

Inclusion:

- Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:

1. MM diagnosis according to the international myeloma working group (IMWG)
diagnostic criteria

2. Measurable disease at screening as assessed by central laboratory

- Received at least 3 prior lines of antimyeloma therapy including a proteasome
inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of
differentiation (CD) 38 monoclonal antibody (mAb)

- Documented evidence of progressive disease(PD) or failure to achieve a response to
the last line of therapy based on investigator's determination of response by the
IMWG criteria

- Have discontinued concurrent use of any other anticancer treatment (including
nonpalliative radiotherapy) or investigational agent

- Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 to 2
at screening and immediately before the start of study treatment administration

Exclusion:

- Suspected or known allergies, hypersensitivity, or intolerance to excipients of
JNJ-79635322

- Had major surgery within 2 weeks before first dose or has planned major surgery
during study treatment phase

- Known active or prior central nervous system (CNS) involvement or exhibits clinical
signs of meningeal involvement of MM

- Participant has leptomeningeal disease

- Participant has a prior or concurrent second malignancy the natural history or
treatment of which could likely interfere with any study endpoints of safety or the
efficacy of the study treatment